The SMx Serum Specialty Matrix Control Sample (Photo courtesy of UTAK LABORATORIES)
Expanded Steroid Control Launched at the 2015 AACC Annual Meeting
|
By LabMedica International staff writers Posted on 30 Jul 2015 |
|
The SMx Serum Specialty Matrix Control Sample (Photo courtesy of UTAK LABORATORIES)
Expanded Steroid Control has been launched that now contains nine analytes of interest at clinically relevant levels for mass spectrometry and separation science technology.
The nine analytes included in the specialty matrix are Corticosterone, Cortisol, Cortisone, Dehydroepiandrosterone (DHEA), Progesterone, 17α-Hydroxyprogesterone, Testosterone, with the addition of Androstenedione and 11 Deoxycortisol.
The Expanded Steroid Control is manufactured by UTAK (Valencia, CA, USA) within its proprietary SMx Serum Specialty Matrix. For use with any methodology, UTAK's stock and custom quality controls are handcrafted and sold to Clinical, Toxicology and Esoteric laboratories globally. UTAK's Expanded Steroid Control in SMx Serum, is offered in individual packs for Levels 1, 2, 3, 4 and a Negative Control. The International Organization for Standardization (ISO) accreditation guidelines note that independent third party quality controls should be used instead of, or in addition to, any control materials supplied by the reagent or instrument manufacturer. UTAK offers hundreds of stock and custom serum, whole blood, urine and oral fluids controls for use with any methodology, on any testing platform.
Jim Plutchak, CEO of UTAK, said, “Our goal is always to craft Quality Controls for Clinical and Esoteric laboratories that are as close to a human matrix as possible. Due to the issue of endogenous steroid levels in serum-based matrix products, we developed a Steroids Control in our SMx Specialty Matrix. The result is a third party control that esoteric laboratories can depend on for their laboratory developed tests.” Charles E. Pippenger, PhD, adjunct professor Department of Neurosciences, University of Vermont College of Medicine added, “Inter-laboratory comparison of results, made possible with a uniform control, allows labs to be confident that test results generated are accurate.”
The Expanded SMx Steroid Control was released at the 2015 American Association of Clinical Chemistry (AACC) Meeting & Clinical Lab Expo held July 26–30, in Atlanta (GA, USA).
Related Links:
UTAK
University of Vermont College of Medicine
American Association of Clinical Chemistry
The nine analytes included in the specialty matrix are Corticosterone, Cortisol, Cortisone, Dehydroepiandrosterone (DHEA), Progesterone, 17α-Hydroxyprogesterone, Testosterone, with the addition of Androstenedione and 11 Deoxycortisol.
The Expanded Steroid Control is manufactured by UTAK (Valencia, CA, USA) within its proprietary SMx Serum Specialty Matrix. For use with any methodology, UTAK's stock and custom quality controls are handcrafted and sold to Clinical, Toxicology and Esoteric laboratories globally. UTAK's Expanded Steroid Control in SMx Serum, is offered in individual packs for Levels 1, 2, 3, 4 and a Negative Control. The International Organization for Standardization (ISO) accreditation guidelines note that independent third party quality controls should be used instead of, or in addition to, any control materials supplied by the reagent or instrument manufacturer. UTAK offers hundreds of stock and custom serum, whole blood, urine and oral fluids controls for use with any methodology, on any testing platform.
Jim Plutchak, CEO of UTAK, said, “Our goal is always to craft Quality Controls for Clinical and Esoteric laboratories that are as close to a human matrix as possible. Due to the issue of endogenous steroid levels in serum-based matrix products, we developed a Steroids Control in our SMx Specialty Matrix. The result is a third party control that esoteric laboratories can depend on for their laboratory developed tests.” Charles E. Pippenger, PhD, adjunct professor Department of Neurosciences, University of Vermont College of Medicine added, “Inter-laboratory comparison of results, made possible with a uniform control, allows labs to be confident that test results generated are accurate.”
The Expanded SMx Steroid Control was released at the 2015 American Association of Clinical Chemistry (AACC) Meeting & Clinical Lab Expo held July 26–30, in Atlanta (GA, USA).
Related Links:
UTAK
University of Vermont College of Medicine
American Association of Clinical Chemistry
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Immunofluorescence Analyzer
IFA System
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! 
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine. 
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest AACC 2015 News
- Automated Molecular Diagnostics System Presented at AACC 2015
- Portable Molecular Diagnostics System Unveiled At 2015 AACC
- Innovative New Technology to Provide Plastic-Exterior Components with Glass Interior, Presented at AACC 2015
- Eco-Friendly Immunoassay Reagents Featured at AACC 2015
- Low Cost Point-of-Care DNA Amplification Test for Chlamydia Infection Demonstrated at the 2015 AACC Annual Meeting
- Inexpensive Multipurpose Point-of-Care Analyzer Unveiled at 2015 AACC Annual Meeting
- State-of-the-Art Automated Laboratory Systems Highlighted at the 2015 AACC Annual Meeting
- Siemens Showcases Multiple New IVD Solutions at AACC 2015
- New HPLC Quadruples Clinical Throughput Capabilities, Displayed at AACC 2015
- Diagnostic Test that Measures Active Renin in Hypertension Displayed at the 2015 AACC Annual Meeting
- Hair Testing May Offer Insights into Asthma-Related Complications in Pregnancy
- Two Newly Developed Tests May Better Diabetes Diagnosis and Monitoring
- CE Marking of Theranostic Monitoring Test Announced at 2015 AACC Annual Meeting
- Ebola Rapid Lateral Flow Test Previewed at the 2015 AACC Annual Meeting
- AACC: Better Quality and Patient-Friendliness Needed in Direct Testing
- Clinical Chemistry Instruments and Reagents Under Scrutiny at the 2015 AACC Annual Meeting
Channels
Clinical Chemistry
view channel
Blood Test Improves Alzheimer’s Diagnosis and Management Across Care Settings
Early and accurate identification of Alzheimer’s disease remains challenging in routine care, particularly outside memory clinics. Confirmation often depends on positron emission tomography (PET) imaging... Read more
New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
Alamar Biosciences (Fremont, CA, USA) has introduced the first commercial immunoassay for enhanced microtubule binding region tau (eMTBR-Tau). The assay is available within the NULISAseq Neuro 220 multiplexed... Read more
Molecular Diagnostics
view channel
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
Many adults inherit genetic changes that increase their risk for cancer and cardiovascular disease, yet access to testing often remains concentrated in large medical centers. Reaching rural and socially... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read more
Pathology
view channel
FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
Prostate cancer is the most common cancer among U.S. men, with more than 300,000 new cases and over 36,000 deaths each year. As targeted therapies emerge for biomarker-defined subgroups, laboratories need... Read more
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more
